oral lung penetrant RSV fusion inhibitor
Ph. II candidate (50 mg BID) for RSV infect.
opt. from literature starting point
J. Med. Chem., Mar. 17, 2021
Reviral Ltd, Hertfordshire, UK
Sisunatovir
The Reviral respiratory syncytial virus (RSV) fusion inhibitor (sisunatovir) is an oral Ph. II clinical candidate that demonstrated reduction in viral load and total symptom score in RSV-infected patients…